AbbVie is a strong investment opportunity with growth potential, dividend income, and a diverse drug portfolio. Find out why ...
Zacks.com on MSN6h
ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?AbbVie ABBV continued its acquisition spree with the announcement of a definitive agreement to acquire private biotech Nimble ...
Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...
UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a ...
Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback